Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: An open randomized controlled trial

Clinical and Experimental Allergy

Volumn 40, Issue 6, 2010, Pages 922-932

  Eifan, A O ^a,b   Akkoc, T ^a   Yildiz, A ^a   Keles, S ^a   Ozdemir, C ^a   Bahceciler, N N ^a   Barlan, I B ^a  

^a MARMARA UNIVERSITY   (Turkey)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Asthma; Cytokines; Nasal provocation; Rhinitis; Sublingual subcutaneous immunotherapy

Indexed keywords

ADRENALIN; ANTIHISTAMINIC AGENT; CORTICOSTEROID; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; RECOMBINANT ALLERGEN; RECOMBINANT BET V 1; RECOMBINANT DER P 1; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ARTHROPOD PROTEIN; CYSTEINE PROTEINASE; DERMATOPHAGOIDES PTERONYSSINUS ANTIGEN P 1;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; ANTIBODY SPECIFICITY; ARTICLE; BRONCHUS HYPERREACTIVITY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RELEASE; DERMATOPHAGOIDES; DRUG EFFICACY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FLUSHING; HUMAN; IMMUNOREACTIVITY; IMMUNOTHERAPY; MALE; NOSE PROVOCATION TEST; OPEN STUDY; PARALLEL DESIGN; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIZATION; SIDE EFFECT; SKIN TEST; SYMPTOM; SYSTEMIC DISEASE; TH1 CELL; TH2 CELL; WHEEZING; ANIMAL; ASTHMA; COMPARATIVE STUDY; DERMATOPHAGOIDES PTERONYSSINUS; HYPERSENSITIVITY; IMMUNOLOGY; PRESCHOOL CHILD; PYROGLYPHIDAE; RHINITIS; SUBCUTANEOUS DRUG ADMINISTRATION; SUBLINGUAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, SUBLINGUAL; ANIMALS; ANTIGENS, DERMATOPHAGOIDES; ARTHROPOD PROTEINS; ASTHMA; CHILD; CHILD, PRESCHOOL; CYSTEINE ENDOPEPTIDASES; DERMATOPHAGOIDES PTERONYSSINUS; FEMALE; HUMANS; HYPERSENSITIVITY; IMMUNOTHERAPY; INJECTIONS, SUBCUTANEOUS; MALE; PYROGLYPHIDAE; RHINITIS; TREATMENT OUTCOME;

EID: 77952088796     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2009.03448.x     Document Type: Article

References (36)

1. Asher MI, Montefort S, Björkstén B et al. ISAAC phase three study group. Lancet 2006 368 : 733 743.
2. Ait-Khaled N, Odhiambo J, Pearce N et al. Prevalence of symptoms of asthma, rhinitis and eczema in 13- to 14-year-old children in Africa: the International Study of Asthma and Allergies in Childhood Phase III. Allergy 2007 62 : 247 258. (Pubitemid 46246500)
3. Bousquet J, Lockey RF, Malling HJ. WHO position paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998 53 : 1 42. (Pubitemid 28346358)
4. Bacharier LB, Boner A, Carlsen KH et al. Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report. Allergy 2008 63 : 5 34. (Pubitemid 350198248)
5. Roberts G, Hurley C, Turcanu V, Lack G. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. J Allergy Clin Immunol 2006 117 : 263 268. (Pubitemid 43190138)
6. Ozdemir C, Yazi D, Gocmen I et al. Efficacy of long-term sublingual immunotherapy as an adjunct to pharmacotherapy in house dust mite-allergic children with asthma. Pediatr Allergy Immunol 2007 18 : 508 515. (Pubitemid 47206743)
7. Di Rienzo V, Pagani A, Parmiani S, Passalacqua G, Canonica GW. Post-marketing surveillance study on the safety of sublingual immunotherapy in pediatric patients. Allergy 1999 54 : 1110 1113. (Pubitemid 29482012)
8. Larché M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 2006 6 : 761 771. (Pubitemid 44453462)
9. Bohle B, Kinaciyan T, Gerstmayr M, Radakovics A, Jahn-Schmid B, Ebner C. Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol 2007 120 : 707 713. (Pubitemid 47320765)
10. Novak N, Haberstok J, Bieber T, Allam JP. The immune privilege of the oral mucosa. Trends Mol Med 2008 14 : 191 198.
11. Global Initiative for Asthma Management and Prevention. NHLBI/WHO Workshop report. GINA Guidelines.
12. Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling HJ, Valovirta E. EAACI, immunotherapy task force. Standards for practical allergen-specific immunotherapy. Allergy 2006 61 (Suppl. 82) : 1 20.
13. Khinchi MS, Poulsen LK, Carat F, André C, Hansen AB, Malling HJ. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 2004 59 : 45 53. (Pubitemid 38167951)
14. Quirino T, Iemoli E, Siciliani E, Parmiani S, Milazzo F. Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study. Clin Exp Allergy 1996 26 : 1253 1261. (Pubitemid 26388998)
15. Mungan D, Misirligil Z, Gürbüz L. Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma - a placebo controlled study. Ann Allergy Asthma Immunol 1999 82 : 485 490. (Pubitemid 29242317)
16. Mauro M, Russello M, Incorvaia C, Gazzola GB, Di Cara G, Frati F. Comparison of efficacy, safety and immunologic effects of subcutaneous and sublingual immunotherapy in birch pollinosis: a randomized study. Eur Ann Allergy Clin Immunol 2007 39 : 119 122. (Pubitemid 46732363)
17. Tahamiler R, Saritzali G, Canakcioglu S, Ozcora E, Dirican A. Comparison of the long-term efficacy of subcutaneous and sublingual immunotherapies in perennial rhinitis. ORL J Otorhinolaryngol Relat Spec 2008 70 : 144 150. (Pubitemid 351595108)
18. Antúnez C, Mayorga C, Corzo JL, Jurado A, Torres MJ. Two year follow-up of immunological response in mite-allergic children treated with sublingual immunotherapy. Comparison with subcutaneous administration. Pediatr Allergy Immunol 2008 19 : 210 218. (Pubitemid 351499165)
19. Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev 2003 CD001186.
20. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007 CD001936. (Pubitemid 46527840)
21. Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy 2005 60 : 4 12.
22. Olaguibel JM, Alvarez Puebla MJ. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis. J Invest Allergol Clin Immunol 2005 15 : 9 16.
23. Penagos M, Compalati E, Tarantini F et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann Allergy Asthma Immunol 2006 97 : 141 148. (Pubitemid 44272577)
24. Walker SM, Pajno GB, Lima MT, Wilson DR, Durham SR. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J Allergy Clin Immunol 2001 107 : 87 93.
25. Francis JN, James LK, Paraskevopoulos G et al. Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity. J Allergy Clin Immunol 2008 121 : 1120 1125.
26. Di Lorenzo G, Mansueto P, Pacor ML et al. Evaluation of serum s-IgE/ total IgE ratio in predicting clinical response to allergen-specific immunotherapy. J Allergy Clin Immunol 2009 123 : 1103 1110.
27. Bahceciler NN, Arikan C, Taylor A et al. Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites. Int Arch Allergy Immunol 2005 136 : 287 294. (Pubitemid 40529201)
28. Cosmi L, Santarlasci V, Angeli R et al. Sublingual immunotherapy with Dermatophagoides monomeric allergoid down-regulates allergen-specific immunoglobulin E and increases both interferon-gamma- and interleukin-10- production. Clin Exp Allergy 2006 36 : 261 272. (Pubitemid 43344707)
29. Gafvelin G, Thunberg S, Kronqvist M et al. Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. Int Arch Allergy Immunol 2005 138 : 59 66. (Pubitemid 41291566)
30. Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Müller UR. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol 1995 154 : 4187 4194.
31. Wachholz PA, Nouri-Aria KT, Wilson DR et al. Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1: Th2 cytokine ratios. Immunology 2002 105 : 56 62.
32. Majori M, Caminati A, Corradi M, Brianti E, Scarpa S, Pesci A. T-cell cytokine pattern at three time points during specific immunotherapy for mite-sensitive asthma. Clin Exp Allergy 2000 30 : 341 347. (Pubitemid 30167249)
33. Gardner LM, Thien FC, Douglass JA, Rolland JM, O'Hehir RE. Induction of T 'regulatory' cells by standardized house dust mite immunotherapy: an increase in CD4+ CD25+ interleukin-10+ T cells expressing peripheral tissue trafficking markers. Clin Exp Allergy 2004 34 : 1209 1219.
34. Arikan C, Bahceciler NN, Deniz G et al. Bacillus Calmette-Guérin- induced interleukin-12 did not additionally improve clinical and immunologic parameters in asthmatic children treated with sublingual immunotherapy. Clin Exp Allergy 2004 34 : 398 405. (Pubitemid 38373002)
35. Dehlink E, Eiwegger T, Gerstmayr M et al. Absence of systemic immunologic changes during dose build-up phase and early maintenance period in effective specific sublingual immunotherapy in children. Clin Exp Allergy 2006 36 : 32 9.
36. Amar SM, Harbeck RJ, Sills M, Silveira LJ, O'Brien H, Nelson HS. Response to sublingual immunotherapy with grass pollen extract: monotherapy versus combination in a multiallergen extract. J Allergy Clin Immunol 2009 124 : 150 156.